Imatinib targets the BCR::ABL1 fusion gene and inhibits Abelson tyrosine kinase, making it widely used to treat chronic myeloid leukemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.